{
  "meta": {
    "title": "Anti-Dyslipidemic",
    "url": "https://brainandscalpel.vercel.app/anti-dyslipidemic-de373f2b.html",
    "scrapedAt": "2025-11-29T18:33:44.511Z"
  },
  "questions": [
    {
      "id": 3828,
      "choices": [
        {
          "id": 15291,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine</span></span></span></p>"
        },
        {
          "id": 15292,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diazoxide</span></span></span></p>"
        },
        {
          "id": 15293,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Minoxidil</span></span></span></p>"
        },
        {
          "id": 15294,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nicorandil</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The side-effect of which of the following drug is used as a therapeutic advantage in alopecia?</span></span></p>",
      "unique_key": "Q6114469",
      "question_audio": null,
      "question_video": null,
      "map_id": 36033,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Minoxidil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Minoxidil </strong>is a medication primarily used to<strong> treat hair loss (alopecia) in both men and women</strong>. Its side effect of <strong>promoting hair</strong> <strong>growth</strong> was discovered incidentally during its <strong>initial use as an oral medication</strong> to treat<strong> high blood pressure</strong>. The topical formulation of <strong>minoxidil</strong> is now <strong>widely used</strong> as a treatment for <strong>androgenetic alopecia (male-pattern baldness and female-pattern hair loss).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hydralazine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hydralazine is an <strong>antihypertensive</strong> medication that<strong> does not</strong> have a therapeutic advantage in <strong>alopecia.</strong> It <strong>does not promote hair growth </strong>and is <strong>not </strong>used in the treatment of<strong> alopecia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Diazoxide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diazoxide is a medication used to<strong> treat hypoglycemia and hypertensive emergencies</strong>. It is<strong> not </strong>associated with any therapeutic advantage in<strong> alopecia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Nicorandil:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nicorandil is a<strong> vasodilator medication </strong>used to treat<strong> angina pectoris.</strong> It <strong>does not </strong>have a therapeutic advantage in <strong>alopecia </strong>and is <strong>not</strong> used for this purpose.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the<strong> therapeutic use of minoxidil</strong> in the treatment of<strong> alopecia </strong>and how its<strong> side effect of</strong> <strong>promoting hair growth</strong> is <strong>exploited for this purpose</strong>. Recognizing medications with <strong>beneficial side effects allows clinicians to repurpose drugs for new indications and optimize patient care.</strong></span></span></span></p>",
      "correct_choice_id": 15293,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3586,
      "choices": [
        {
          "id": 14323,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></p>"
        },
        {
          "id": 14324,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxycodone</span></span></span></p>"
        },
        {
          "id": 14325,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban </span></span></span></p>"
        },
        {
          "id": 14326,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adalimumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is taking atorvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?<strong> </strong></span></span></span></p>",
      "unique_key": "Q8659814",
      "question_audio": null,
      "question_video": null,
      "map_id": 36031,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Clarithromycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clarithromycin </strong>should be <strong>avoided</strong> in patients taking <strong>atorvastatin for dyslipidemia</strong>. Atorvastatin, like other <strong>statins,</strong> is <strong>metabolized</strong> by the <strong>cytochrome P450 3A4 (CYP3A4) enzyme system</strong>. Clarithromycin is a known <strong>inhibitor of the CYP3A4 enzyme,</strong> which can lead to <strong>increased plasma levels of atorvastatin.</strong> When its <strong>plasma levels rise </strong>significantly, there is an<strong> increased risk of serious adverse effects</strong> such as <strong>myopathy</strong>, which includes<strong> muscle pain, tenderness, or weakness</strong> with elevated levels of<strong> creatine kinase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Oxycodone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because oxycodone, an<strong> opioid analgesic,</strong> <strong>does not</strong> significantly interact with the<strong> CYP3A4 enzyme</strong> in a way that would affect the <strong>metabolism of atorvastatin to a clinically relevant extent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rivaroxaban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>rivaroxaban,</strong> an <strong>anticoagulant</strong>, is<strong> not metabolized by CYP3A4</strong> in a way that would interfere with <strong>atorvastatin metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Adalimumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>adalimumab</strong>, an <strong>immunosuppressive drug</strong> used to treat <strong>autoimmune diseases, does not</strong> interact with the<strong> CYP3A4 enzyme </strong>and thus<strong> would not </strong>affect <strong>atorvastatin levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When prescribing <strong>statins,</strong> <strong>avoid </strong>concomitant use with drugs that<strong> inhibit CYP3A4,</strong> such as <strong>clarithromycin,</strong> to prevent an<strong> increase</strong> in their <strong>plasma levels</strong> which could <strong>lead to myopathy. </strong>Other notable<strong> CYP3A4 inhibitors</strong> to avoid include <strong>amiodarone, gemfibrozil, HIV</strong> <strong>protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</strong></span></span></span></p>",
      "correct_choice_id": 14323,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3747,
      "choices": [
        {
          "id": 14967,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old woman with type 1 diabetes with two positive spot microalbuminuria tests 1 week apart</span></span></span></p>"
        },
        {
          "id": 14968,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with type 1 diabetes with a blood glucose of 328 mg/dL and a positive spot microalbuminuria test</span></span></span></p>"
        },
        {
          "id": 14969,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old man with type 2 diabetes with a positive spot microalbuminuria test 1 week after starting a new exercise program</span></span></span></p>"
        },
        {
          "id": 14970,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart&nbsp;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following patients should be treated with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker?</span></span></span></p>",
      "unique_key": "Q6591996",
      "question_audio": null,
      "question_video": null,
      "map_id": 36032,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> use of ACE inhibitors or ARBs</strong> is indicated in patients with diabetes who exhibit <strong>persistent microalbuminuria, </strong>as this is a marker of <strong>early diabetic nephropathy. </strong>It is<strong> essential to confirm persistent microalbuminuria </strong>with at<strong> least two positive tests</strong> <strong>spaced 3 to 6</strong> months apart, in the absence of other conditions that might<strong> cause transient increases in albumin excretion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The testing <strong>interval of 1 week</strong> is too soon for confirmation of <strong>persistent microalbuminuria. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The presence of<strong> severe hyperglycemia </strong>can <strong>transiently increase albumin excretion</strong>, potentially confounding the <strong>test result. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Vigorous exercise </strong>can also transiently <strong>increase albumin excretion,</strong> making the test result unreliable.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of<strong> diabetic nephropathy, ACE inhibitors or ARBs </strong>should be initiated in patients with <strong>type 2 diabetes</strong> who have <strong>confirmed persistent microalbuminuria, </strong>indicated by <strong>at least two positive microalbuminuria tests </strong>spaced<strong> 3 to 6 months </strong>apart, <strong>without </strong>the influence of <strong>confounding factors.</strong></span></span></span></p>",
      "correct_choice_id": 14970,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}